M&As this week: Pfizer, KDB Capital
Pfizer has acquired 50% stake in IGNITE Immunotherapy. Pursuant to the acquisition, Pfizer will hold 50% equity investment in IGNITE and be responsible for providing research and development funding for three years.
The acquisition will allow Pfizer to develop a new research programme to discover novel vaccinia viruses and also to expand its presence in the immuno-oncology field.
KDB Capital has acquired 6.7% stake in Anygen.
The acquirer is a financial services provider company, while the target is a peptide synthesis provider.
Image: Pfizer has acquired 50% stake in IGNITE Immunotherapy.